Neil Glat Purchases Shares of Evolv Technologies
Neil Glat bought 28,318 shares of Evolv Technologies Holdings, Inc. on June 18, 2026.
Key Points
- Neil Glat acquired 28,318 shares of Evolv Technologies on June 18, 2026, with the stock trading near $5.54 on Tuesday.
- Evolv Technologies has a market cap of $1.02 billion and faces challenges with a negative forward P/E due to unprofitability.
- Analysts maintain a strong buy consensus with a mean target price of $10.13, highlighting potential growth.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Neil Glat, an insider at Evolv Technologies Holdings, Inc., bought 28,318 shares of the company on June 18, 2026. The transaction was not part of a pre-planned trading program. On Tuesday, the shares of Evolv Technologies, trading under the ticker NasdaqCM:EVLV, were priced near $5.54.
Insider Buying and Selling at Evolv Technologies Holdings, Inc.
In addition to Neil Glat, several other insiders at Evolv Technologies, including Kevin Charlton, Michael Ellenbogen, Richard Shapiro, Kimberly Sheehy, and Henrik Kuhl, each purchased 28,318 shares on June 18, 2026. These transactions were also not under Rule 10b5-1 plans.
Evolv Technologies Holdings, Inc. Stock Up 5.7%
As of Tuesday, shares of Evolv Technologies Holdings, Inc. traded near $5.54. The company, with a market capitalization of approximately $1.02 billion, operates in the security and protection services industry. Despite its innovative offerings, Evolv faces profitability challenges, evidenced by a negative forward P/E ratio. The stock's 52-week range spans from $4.87 to $8.91, and it has a beta of 1.756, indicating higher volatility compared to the market. Evolv's financial health includes a current ratio of 1.207 and a quick ratio of 0.834, with a debt-to-equity ratio of 34.78.
$EVLV stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 9, 2026, TD Cowen reiterated its buy rating for Evolv Technologies with a $10 price target. The analyst consensus remains strong buy, with a mean target price of $10.13 based on four analyst opinions. This suggests a positive outlook among analysts despite the company's current financial hurdles.
About Evolv Technologies Holdings, Inc.
Evolv Technologies Holdings, Inc. develops and markets advanced security screening products. Headquartered in Waltham, Massachusetts, the company is led by CEO John Kedzierski. Evolv's technology, including the Evolv Express and eXpedite systems, is used to detect weapons in crowded areas, serving industries from healthcare and education to entertainment and government facilities. Founded in 2013, the company employs 286 people and continues to expand its reach in the security sector.
Bottom Line
Neil Glat's recent purchase of Evolv Technologies shares underscores insider confidence in the company's potential. While the company is currently not profitable, analysts maintain a strong buy consensus, indicating optimism for future growth. Investors should note that insider transactions and analyst ratings are just part of the information needed for comprehensive investment decisions.
Get Evolv Technologies Holdings, Inc. alerts
New 13F filings, insider trades, and analyst moves on $EVLV, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.